申请人:OTSUKA PHARMACEUTICAL CO., LTD.
公开号:US10626095B2
公开(公告)日:2020-04-21
This invention relates to a cyanotriazole compound represented by the formula (1):
wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.
本发明涉及一种由式(1)表示的氰三唑化合物:
其中各符号在说明书中定义,或其盐。该化合物或其盐可刺激柠檬酸循环活性和/或改善高血糖,且副作用小、安全性高,因此可用于治疗和/或预防柠檬酸循环激活和/或改善高血糖具有预防和/或治疗作用的疾病或紊乱、例如,糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、肝脂肪变性、动脉粥样硬化和/或心血管疾病,以及可从刺激能量消耗中获益的疾病或紊乱。